[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fluid-therapy-during-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fluid-therapy-during-surgery":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644754","remimazolam-on-the-incidence-of-postoperative-acute-kidney-injury-100644754",false,"NCT07674719","Remimazolam on the Incidence of Postoperative Acute Kidney Injury","The Effect of Intraoperative Remimazolam Administration on the Incidence of Postoperative Acute Kidney Injury After Hepatobiliary and Pancreatic Surgery : a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Ages 19 or older and under 85\n* Patients scheduled to undergo elective hepatopancreatic surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical grade 1-3\n* Those who voluntarily consented to a written informed consent form prior to participation in the study\n\nExclusion Criteria:\n\n* Patients with hypersensitivity to other benzodiazepine drugs, including remimazolam, and to the components of this drug (e.g., patients with severe hypersensitivity to dextran 40)\n* Patients with hypersensitivity to propofol\n* Patients with underlying conditions: liver, neurological disorders, or acute narrow-angle glaucoma\n* Patients with severe or acute respiratory failure\n* Patients in shock or a coma\n* Patients taking TCA antidepressants\n* Patients with preoperative chronic kidney disease","ALL","19 Years","85 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.",[27,28,29,30,31,32,33],"Remimazolam","Propofol","Acute Kidney Injury","Hemodynamic Stability","Hepatobiliary Surgery","Fluid Therapy","Fluid Therapy DURING SURGERY","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":21},"2026-06-26",{"date":42,"type":21},"2028-06-26",{"name":44,"class":45},"Seoul National University Bundang Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100617148","using-artificial-intelligence-to-guide-fluid-therapy-during-major-cancer-surgery-a-randomized-controlled-trial-100617148","NCT07314853","Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled Trial","Fluid Optimization in Cancer Surgery With AI-Assisted Management - FOCUS-AFM Trial","FOCUS-AFM","Inclusion Criteria:\n\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) Physical Status II-IV\n* Undergoing major abdominal oncologic surgery (open or laparoscopic) with an expected duration \\>2 hours\n* Planned invasive arterial pressure monitoring\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Significant arrhythmias (e.g., persistent atrial fibrillation)\n* Severe aortic stenosis\n* Emergency surgery\n* Sepsis\n* End-stage renal disease on dialysis\n* Pregnancy\n* Impossibility to cannulate the radial artery\n* Refusal to participate or refusal of data processing consent","18 Years",{"count":57,"type":21},176,[24],"The goal of this clinical trial is to learn if using artificial intelligence to guide intravenous fluid therapy during major cancer surgery can help keep blood pressure more stable compared with usual care in adult patients undergoing major cancer surgery. The main questions it aims to answer are:\n\n* Does artificial intelligence-guided fluid therapy reduce hypotensive events during surgery?\n* Does this approach improve recovery and reduce complications after major cancer surgery?\n\nResearchers will compare artificial intelligence-guided fluid therapy with standard fluid management to see if the artificial intelligence-guided approach provides better support during surgery.\n\nParticipants will:\n\n* Undergo major cancer surgery under general anesthesia\n* Receive either artificial intelligence-guided fluid management or standard fluid management during surgery\n* Be monitored during and after surgery as part of routine clinical care\n* Be followed after surgery to assess recovery and possible complications",[61,62,63,64,65,33],"Neoplasm","Cancer","Hemodynamic (MAP) Stability","Cancer Surgery","Artificial Intelligence (AI)",[67,68,69,70,71],"randomized controlled trial","cancer","fluid balance","fluid therapy","artificial intelligence","2026-01-07",{"date":74,"type":38},"2026-01-09",{"date":76,"type":21},"2026-02",{"date":78,"type":21},"2029-02",{"name":80,"class":45},"National Cancer Institute, Naples"]